Dietary Fibre and Chromium Picolinate Efficacy in Overweight and Obese Women

NCT ID: NCT04250831

Last Updated: 2020-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-12

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is one of the greatest causes of preventable morbidity and mortality worldwide with the main treatments requiring significant changes to lifestyle, particularly dieting and physical exercise. Glucomannan is a dietary fibre that expands in the stomach, creating the feeling of fulness, while chromium can regulate insulin response.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this pilot study was to investigate the effect of agglomerated glucomannan, oligofructose and chromium, as part of a calorie restricted diet plan, on weight loss, satiety, satiation, mood and gut microbiome composition in a human intervention study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hormones microbiota mood hunger weight loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single group, prospective, open label pilot human intervention study
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucomannan, oligofructose and chromium mixture

Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie

Group Type EXPERIMENTAL

agglomerated glucomannan, oligofructose and chromium mixture

Intervention Type DIETARY_SUPPLEMENT

Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

agglomerated glucomannan, oligofructose and chromium mixture

Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy female
* aged 18-65 years
* with a BMI between 25 and 35 kg/m2
* not dieting within the previous four months
* not having lost \> 5% body weight in the previous year
* not having increased physical activity levels in the past 2-4 weeks
* intending to modify them during the study
* able to eat most everyday foods

Exclusion Criteria

* BMI \< 25 kg/m2
* \> 35 kg/m2
* significant health problems
* taking any medication or supplements known to affect appetite
* weight within the past month and/or during the study
* pregnant, planning to become pregnant or breastfeeding
* history of anaphylaxis to food
* known allergies or intolerance to foods and/or to the study materials or any of their stated ingredients.
* Volunteers who were on specific food avoidance diets
* with abnormal eating behaviour
* receiving systemic or local treatment likely to interfere with the evaluation of the study parameters
* smokers and those who have recently ceased smoking
* Volunteers who work in appetite or feeding related areas volunteers who participated in another experimental study or receipt of
Minimum Eligible Age

22 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Roehampton

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

DR ADELE COSTABILE

PI

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ADELE COSTABILE, Dr

Role: STUDY_DIRECTOR

Roehampton University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Health Sciences Research Centre, Life Sciences Department, University of Roehampton

London, UK, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSC 18/238

Identifier Type: -

Identifier Source: org_study_id